	US 7,514,420 B2
	Steroids having 1,8-unsaturation and formulations comprising same
Henry A. Lardy, Madison, Wis. (US); Padma Marwah, Madison, Wis. (US); and Ashok Marwah, Madison, Wis. (US)
Assigned to Hollis-Eden Pharmaceuticals, Inc., San Diego, Calif. (US)
Filed on Aug. 13, 2007, as Appl. No. 11/838,154.
Application 11/838154 is a continuation of application No. 10/814503, filed on Mar. 30, 2004, abandoned.
Claims priority of provisional application 60/459450, filed on Apr. 01, 2003.
Prior Publication US 2008/0004250 A1, Jan. 03, 2008
Int. Cl. A61K 31/56 (2006.01); A61K 31/58 (2006.01); C07J 5/00 (2006.01); C07J 7/00 (2006.01); C07J 21/00 (2006.01); C07J 71/00 (2006.01)

U.S. Cl. 514—173 [514/179; 514/182; 540/6; 540/23; 552/582; 552/592]

21 Claims

1. A compound having the structure

or a pharmaceutically acceptable salt of the compound wherein,

A is —CR⁹R¹⁰—;

E is —C(O)— or —CR⁵R⁶—;

G is —CR³R⁴—;

K is —CR¹R²—;

R and R′ independently are —F, —Cl, —Br, —I, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkene, substituted or unsubstituted lower alkyne, —CN, —COOR¹⁴, —C(O)NR¹⁴R¹⁵, —NO₂, —NR¹⁴R¹⁵, —NR¹⁴—C(O)—R¹⁵, —OH, substituted or unsubstituted lower alkoxy, or —S(O)_0-2R¹⁴;

R¹is —OR¹¹;

wherein R¹¹is —H, substituted or unsubstituted alkyl, substituted or unsubstituted alkene, substituted or unsubstituted alkyne, —C(O)—R¹², —C(O)—NR¹²R¹³, —C(O)—OR¹², —C(S)—R¹², —NR¹²R¹³, —S(O)₂—R¹², —S(O)₂—OR¹², or —P(O)(OR¹²)(OR¹³)_0-1;

R²is —H, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkene or substituted or unsubstituted lower alkyne;

R³and R⁵independently are —H, —F, —CI, —Br, —I, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkene or substituted or unsubstituted lower alkyne;

R⁴and R⁶independently are —H, —COOR¹⁴, —C(O)NR¹⁴R¹⁵, —NO₂, —NR¹⁴R¹⁵, —NR¹⁴—C(O)—R¹⁵, —OH or substituted or unsubstituted lower alkoxy;

R⁷and R⁸independently are —H or substituted or unsubstituted lower alkyl;

R⁹is —OH or substituted or unsubstituted lower alkoxy;

R¹⁰is substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkene, substituted or unsubstituted lower alkyne, substituted or unsubstituted —S(O)_0-2(lower alkyl) or R⁹and R¹⁰, together with the carbon to which they are attached, form a 5-, 6-, or 7- member heterocyclyl or cycloalkyl group;

R¹²and R¹³independently are —H, substituted or unsubstituted alkyl, substituted or unsubstituted alkene, or substituted or unsubstituted alkyne;

R¹⁴and R¹⁵independently are —H, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkene, substituted or unsubstituted lower alkyne, substituted or unsubstituted C_6-10aryl, or substituted or unsubstituted C_7-12arylalkyl;

n is 0, 1, or 2; and

n′ is 0, 1, or 2.